Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO Sells 12,322 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CFO William Garrett Gray sold 12,322 shares of the business’s stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $4.05, for a total transaction of $49,904.10. Following the completion of the sale, the chief financial officer now owns 1,446,322 shares in the company, valued at $5,857,604.10. This represents a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

William Garrett Gray also recently made the following trade(s):

• On Thursday, February 6th, William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ:CKPT opened at $4.01 on Friday. The firm has a market capitalization of $195.82 million, a PE ratio of -2.18 and a beta of 1.21. The business has a 50 day simple moving average of $3.42 and a two-hundred day simple moving average of $3.31. Checkpoint Therapeutics, Inc. has a 1 year low of $1.38 and a 1 year high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last posted its quarterly earnings results on Friday, March 28th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.47). The firm had revenue of $0.04 million for the quarter. Equities research analysts expect that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Institutional Trading of Checkpoint Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Checkpoint Therapeutics by 226.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 425,000 shares of the company’s stock valued at $1,360,000 after buying an additional 295,000 shares in the last quarter. 683 Capital Management LLC purchased a new position in Checkpoint Therapeutics in the fourth quarter worth $522,000. Geode Capital Management LLC increased its position in shares of Checkpoint Therapeutics by 41.2% during the third quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock worth $958,000 after purchasing an additional 124,787 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in shares of Checkpoint Therapeutics during the 4th quarter valued at $374,000. Finally, Bank of America Corp DE boosted its position in shares of Checkpoint Therapeutics by 30,216.8% in the 4th quarter. Bank of America Corp DE now owns 90,041 shares of the company’s stock worth $288,000 after purchasing an additional 89,744 shares in the last quarter. 22.00% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on CKPT. D. Boral Capital reiterated a “buy” rating and issued a $4.80 price target on shares of Checkpoint Therapeutics in a research report on Monday, March 31st. Lake Street Capital restated a “hold” rating and set a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. Finally, HC Wainwright restated a “neutral” rating and issued a $4.10 price target on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.